Cash & Equivalents
AbbVie Cash & Equivalents decreased by 7.1% to $5.23B in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 5.3%, from $5.52B to $5.23B. Over 5 years (FY 2020 to FY 2025), Cash & Equivalents shows a downward trend with a -9.2% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase signals improved liquidity and financial flexibility, while a decrease may indicate heavy capital expenditure, debt repayment, or aggressive share buybacks.
Detailed definition
Represents the most liquid assets on the balance sheet, including physical currency and short-term investments with matu...
Peer comparison
Large-cap technology peers often maintain high cash balances to fund rapid innovation and offset the cyclical nature of consumer electronics.
cash_and_equivalentsHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $8.55B | $12.18B | $9.75B | $6.10B | $8.52B | $11.83B | $9.20B | $6.71B | $8.76B | $13.29B | $12.81B | $18.07B | $13.13B | $7.26B | $5.52B | $5.18B | $6.47B | $5.63B | $5.23B |
| QoQ Change | — | +42.5% | -20.0% | -37.4% | +39.7% | +38.9% | -22.2% | -27.1% | +30.5% | +51.7% | -3.6% | +41.0% | -27.3% | -44.7% | -23.9% | -6.3% | +25.0% | -13.0% | -7.1% |
| YoY Change | — | — | — | — | -0.3% | -2.9% | -5.6% | +10.1% | +2.8% | +12.3% | +39.3% | +169.2% | +49.9% | -45.4% | -56.9% | -71.4% | -50.7% | -22.4% | -5.3% |
Cash & Equivalents at Other Companies
Frequently Asked Questions
- What is AbbVie's cash & equivalents?
- AbbVie (ABBV) reported cash & equivalents of $5.23B in Q4 2025.
- How has AbbVie's cash & equivalents changed year-over-year?
- AbbVie's cash & equivalents decreased by 5.3% year-over-year, from $5.52B to $5.23B.
- What is the long-term trend for AbbVie's cash & equivalents?
- Over 5 years (2020 to 2025), AbbVie's cash & equivalents has grown at a -9.2% compound annual growth rate (CAGR), from $8.45B to $5.23B.
- What does cash & equivalents mean?
- Money in the bank and very short-term investments that can be turned into cash almost instantly.